keyword
MENU ▼
Read by QxMD icon Read
search

Skeletal metastases

keyword
https://www.readbyqxmd.com/read/28324746/denosumab-in-advanced-unresectable-giant-cell-tumour-of-bone-gctb-for-how-long
#1
E Palmerini, N S Chawla, S Ferrari, M Sudan, P Picci, E Marchesi, M Piccinni Leopardi, I Syed, K K Sankhala, P Parthasarathy, W E Mendanha, M Pierini, A Paioli, S P Chawla
BACKGROUND: Giant-cell tumours of bone (GCTB) are RANK/RANK-ligand (RANKL) positive, aggressive and progressive osteolytic tumours. Denosumab, a RANKL inhibitor, was FDA-approved for adults and skeletally mature adolescents with unresectable GCTB or when surgical resection is likely to result in severe morbidity. Data on long-term toxicity and activity of denosumab monthly 'GCTB-schedule' (120 mg per 12/year, 1440 mg total dose/year) are lacking. METHODS: Patients with GCTB receiving denosumab, 120 mg on days 1, 8, 15, 29 and every 4 weeks thereafter, from 2006 to 2015 treated in two centres were included...
March 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28324052/skeletal-complications-and-mortality-in-thyroid-cancer-a-population-based-study
#2
Palak Choksi, Maria Papaleontiou, Cui Guo, Francis Worden, Mousumi Banerjee, Megan Haymart
Context: Although bone is a common site for tumor metastases, the burden of bone events (bone metastases and skeletal-related events (SREs)) in patients with thyroid cancer is not well known. Objective: To measure the prevalence of bone events and their impact on mortality in patients with thyroid cancer. Patients, Design, and Setting: We identified patients diagnosed with thyroid cancer between 1991-2011 from the linked Surveillance Epidemiology and End Results-Medicare (SEER-Medicare) dataset...
January 25, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28292438/maoa-dependent-activation-of-shh-il6-rankl-signaling-network-promotes-prostate-cancer-metastasis-by-engaging-tumor-stromal-cell-interactions
#3
Jason Boyang Wu, Lijuan Yin, Changhong Shi, Qinlong Li, Peng Duan, Jen-Ming Huang, Chunyan Liu, Fubo Wang, Michael Lewis, Yang Wang, Tzu-Ping Lin, Chin-Chen Pan, Edwin M Posadas, Haiyen E Zhau, Leland W K Chung
Metastasis is a predominant cause of death for prostate cancer (PCa) patients; however, the underlying mechanisms are poorly understood. We report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PCa bone and visceral metastases, activating paracrine Shh signaling in tumor-stromal interactions. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6...
March 13, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28291739/a-radiobiological-model-of-metastatic-burden-reduction-for-molecular-radiotherapy-application-to-patients-with-bone-metastases
#4
Ana M Denis-Bacelar, Sarah J Chittenden, Iain Murray, Antigoni Divoli, V Ralph McCready, David P Dearnaley, Joe M O'Sullivan, Bernadette Johnson, Glenn D Flux
Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient...
April 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28279906/preparation-and-evaluation-of-rhenium-188-pamidronate-as-a-palliative-treatment-in-bone-metastasis
#5
Mostafa Erfani, Nasim Rahmani, Alireza Doroudi, Mohammad Shafiei
OBJECTIVE: Rhenium-188-hydroxyethylidene diphosphonate ((188)Re-HEDP) as a first generation bisphosphonate has been widely used for bone seeking radiopharmaceutical in cases of metastatic bone disease. No study has been yet reported on preparing a complex of (188)Re with pamidronate (3-aminohydroxypropylidene-1,1-bisphosphonic acid) (PMA) as a second generation bisphosphonate. Based on this fact, it was hypothesized that a bone-seeking (188)Re-PMA radiopharmaceutical could be developed as an agent for palliative radiotherapy of bone pain due to skeletal metastases...
February 24, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28278446/fluorocholine-pet-ct-predicts-skeletal-progression-skeletal-event-and-cancer-specific-survival-in-patients-with-biochemical-relapse-for-prostate-cancer
#6
Fabio Zattoni, Emanuela Agostini, Francesco Cattaneo, Marco Maruzzo, Umberto Basso, Filiberto Zattoni, Laura Evangelista
PURPOSE: The aim of our study is to evaluate the prognostic impact of (18)F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse. METHODS: We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy...
February 24, 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28277852/the-treatment-patterns-of-castration-resistant-prostate-cancer-in-japan-including-symptomatic-skeletal-events-and-associated-treatment-and-healthcare-resource-use
#7
Hiroji Uemura, Marco DiBonaventura, Ed Wang, Dianne Athene Ledesma, Kristen Concialdi, Yasuko Aitoku
BACKGROUND: Real-world treatment patterns of bone metastatic castration-resistant prostate cancer (mCRPC) in Japan were examined, focusing on treatment patterns and resource use differences attributed to symptomatic skeletal events (SSEs). METHODS: Urologists (N=176) provided retrospective chart data for patients with mCRPC (N=445) via online surveys. Descriptive analyses and chi-square tests evaluated treatment patterns and their differences by SSE presence; generalized linear mixed models examined healthcare resource utilization differences as a function of SSEs...
March 6, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28274851/emerging-therapeutic-targets-in-cancer-induced-bone-disease-a-focus-on-the-peripheral-type-2-cannabinoid-receptor
#8
REVIEW
Silvia Marino, Aymen I Idris
Skeletal complications are a common cause of morbidity in patients with primary bone cancer and bone metastases. The type 2 cannabinoid (Cnr2) receptor is implicated in cancer, bone metabolism and pain perception. Emerging data have uncovered the role of Cnr2 in the regulation of tumour-bone cell interactions and suggest that agents that target Cnr2 in the skeleton have potential efficacy in the reduction of skeletal complications associated with cancer. This review aims to provide an overview of findings relating to the role of Cnr2 receptor in the regulation of skeletal tumour growth, osteolysis and bone pain, and highlights the many unanswered questions and unmet needs...
March 6, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28274254/the-use-of-randomisation-based-efficacy-estimators-in-non-inferiority-trials
#9
David Gillespie, Daniel Farewell, Peter Barrett-Lee, Angela Casbard, Anthony Barney Hawthorne, Chris Hurt, Nick Murray, Chris Probert, Rachel Stenson, Kerenza Hood
BACKGROUND: In a non-inferiority (NI) trial, analysis based on the intention-to-treat (ITT) principle is anti-conservative, so current guidelines recommend analysing on a per-protocol (PP) population in addition. However, PP analysis relies on the often implausible assumption of no confounders. Randomisation-based efficacy estimators (RBEEs) allow for treatment non-adherence while maintaining a comparison of randomised groups. Fischer et al. have developed an approach for estimating RBEEs in randomised trials with two active treatments, a common feature of NI trials...
March 9, 2017: Trials
https://www.readbyqxmd.com/read/28272651/subcutaneous-leiomyosarcoma-metastasized-to-the-lymph-nodes-involved-with-small-lymphocytic-lymphoma-chronic-lymphocytic-leukemia
#10
Ayfer Kamali Polat, Atilla Soran, Amal Kanbour-Shakir, Howard Edington
Herein, we present a case of a 76-year-old Caucasian man with a very large fungating, ulcerating mass, involving the right neck and parotid area, which developed while he was being treated for chronic lymphocytic leukemia/small lymphocytic lymphoma. Resection of the fungating right neck tumor, right modified radical neck dissection, and right superficial parotidectomy with flap reconstruction were performed. The final pathological diagnosis was high-grade leiomyosarcoma of the skin and the subcutaneous tissue, with invasion into the skeletal muscle, skin, and soft tissue...
February 4, 2017: Türk Patoloji Dergisi
https://www.readbyqxmd.com/read/28263211/extraneural-metastases-from-desmoplastic-medulloblastoma-masquerading-as-lymphoma
#11
Abhishek Mahajan, Peter Paul, Epari Sridhar, Venkatesh Rangarajan, Tejpal Gupta, Girish Chinnaswamy, Aliasgar Moiyadi, Rakesh Jalali
Medulloblastoma is a WHO grade IV neoplasm that is usually restricted to the central nervous system, with metastasis occurring along the neuraxis through the ventricular system and cerebrospinal fluid. Extraneural metastasis is rare, usually occurs in bones/lymph nodes, and carries poor prognosis. We report multimodal imaging in a 14-year-old boy with desmoplastic medulloblastoma having multiple extraneural nodal and skeletal metastases, which was misdiagnosed as lymphoma. This case highlights the importance of understanding tumor biology with active clinical and radiological surveillance that is useful in early detection of extraneural metastasis of this aggressive tumor that helps in advocating appropriate and timely treatment...
March 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28263210/incremental-value-of-cocktail-18-f-fdg-and-18-f-naf-pet-ct-over-18-f-fdg-pet-ct-alone-for-characterization-of-skeletal-metastases-in-breast-cancer
#12
Mohan J Roop, Baljinder Singh, Harmandeep Singh, Ankit Watts, Pavneet S Kohli, Bhagwant R Mittal, Gurpreet Singh
PURPOSE: The aim of this study was to evaluate the incremental value of cocktail F-FDG/F-NaF PET/CT over F-FDG PET/CT alone for detection of skeletal metastases in breast cancer patients. METHODS: Seventy patients with locally advanced/recurrent breast cancer were prospectively included. All patients underwent whole-body F-FDG PET/CT and cocktail F-FDG/F-NaF PET/CT within a span of 1 week. Both studies were evaluated to detect presence of skeletal/marrow metastases on PET/CT images by 2 nuclear medicine physicians...
March 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28258443/semi-quantitative-scoring-of-skeletal-metastases-by-123-i-mibg-scintigraphy-in-high-risk-neuroblastoma
#13
EDITORIAL
Mark N Gaze
No abstract text is available yet for this article.
March 3, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28244474/the-longest-tumor-diameter-in-one-dimension-as-a-predictor-for-skeletal-metastasis-in-renal-cell-carcinoma
#14
And Dwivedi, A Srinivasan, S Kumar, S Trivedi, V K Shukla, R C Shukla
INTRODUCTION: Renal cell carcinoma (RCC) comprises a diverse group of malignant neoplasms that have multifarious histopathological features and biological behavior. One-third of RCC patients develops skeletal metastasis with a poor 5-year survival rate. Data explaining how some of these tumors show sooner bony metastasis than expected is sparse. The objective of this study was to identify whether tumor size can act as a predictor of bony metastases among patients of RCC. MATERIALS AND METHODS: We retrospectively reviewed contrast enhanced computed tomography (CECT) scan and clinical records of 66 patients with RCC, who fulfilled specified inclusion criteria...
July 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28230714/assessment-of-skeletal-tumour-burden-on-18f-naf-pet-ct-using-a-new-quantitative-method
#15
Paula Lapa, Margarida Marques, Gracinda Costa, Andrei Iagaru, João Pedroso de Lima
PURPOSE: The purpose of this study was to test a method of quantifying skeletal tumour burden with F-NaF PET/CT. PATIENTS AND METHODS: We retrospectively reviewed the charts of 117 patients who underwent F-NaF PET/CT for the detection of bone metastases, 68 women and 49 men, 16-82 years old (mean±SD: 62.9±10.7 years). Mean standardized uptake values (SUVmean) were measured in five anatomic sites to evaluate normal skeleton activity. The influence of sex and age was investigated...
April 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28220804/impact-of-symptomatic-skeletal-events-on-health-care-resource-utilization-and-quality-of-life-among-patients-with-castration-resistant-prostate-cancer-and-bone-metastases
#16
R McKay, B Haider, M S Duh, A Valderrama, M Nakabayashi, M Fiorillo, L Ristovska, L Wen, P Kantoff
BACKGROUND: Data regarding the impact of symptomatic skeletal events (SSEs) on health economics and patient-reported outcomes in men with castration-resistant prostate cancer (CRPC) and bone metastases from a clinical setting are lacking. Hence, this study aimed to quantify the effects of SSEs on health-care resource utilization (HRU), health-related quality of life (HRQoL) and pain in men with CRPC metastasized to bone. METHODS: This cohort study included men with CRPC and bone metastasis treated at a tertiary center during December 1996-July 2015...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28220258/impact-of-denosumab-use-on-the-survival-of-untreated-non-squamous-non-small-cell-lung-cancer-patients-with-bone-metastases
#17
Hibiki Udagawa, Seiji Niho, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
PURPOSE: Denosumab reduces the incidence of skeletal-related events (SREs) in solid tumor patients with bone metastases (BM). However, there have been no detailed reports of the efficacy of denosumab in untreated non-squamous non-small cell lung cancer (NSCLC) patients with BM. METHODS: The medical records of patients with untreated non-squamous NSCLC and BM at diagnosis at our institution were reviewed retrospectively. The overall survival (OS) and the time to SREs were analyzed according to the treatment for the BM...
February 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28218377/current-orthopaedic-management-of-bony-metastases-in-the-proximal-third-of-the-femur
#18
Sam C Jonas, Sanchit M Mehendale, Simon M Bick, Richard P Baker
Patients presenting with skeletal metastatic lesions requiring surgery are increasing, this is due to an ageing population and improved oncological survival following advances in medical management. Furthermore, patients are living longer with skeletal metastatic disease. The majority of bone metastases occur in the proximal femur. Robust diagnosis (Biopsy) and treatment is required to ensure that patients can mobilise fully weight bearing immediately post-surgery and that the construct should outlive the patients expected survival...
February 21, 2017: Hip International: the Journal of Clinical and Experimental Research on Hip Pathology and Therapy
https://www.readbyqxmd.com/read/28217018/skeletal-metastases-presenting-as-superscan-on-technetium-99m-methylene-diphosphonate-whole-body-bone-scintigraphy-in-different-type-of-cancers-a-5-year-retro-prospective-study
#19
P Ram Manohar, Tanveer A Rather, Shoukat H Khan, Dharmender Malik
The purpose of the study is to find out the overall incidence of superscan among different type of cancers, causes of superscan and its relationship with other parameters such as age, sex, duration of disease, and serum alkaline phosphatase (ALP) levels. This was a retro-prospective study. Records of all previous bone scans and reported patients of superscan were re-evaluated retrospectively. Patients who were diagnosed as having superscan in the preceding 3 years with confirmed histopathological diagnosis were included in the retrospective group...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28217016/prostate-specific-antigen-as-a-risk-factor-for-skeletal-metastasis-in-native-ethnic-african-men-with-prostate-cancer-a-case-control-study
#20
Ayman M Qureshi, Khalid Makhdomi, William Stones
Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels of prostate-specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in patients with low prostate specific antigen levels have drawn attention to the matter...
January 2017: World Journal of Nuclear Medicine
keyword
keyword
109657
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"